Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium

Inclusion Criteria: * Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma. Indication for radioembolization validated after pluridisciplinary committee meeting. * Isolated target on initial imagery (invasive hepatocellular carcinoma excluded) * WHO (World Health organization) Performance status: 0, 1 or 2 * If cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter * Creatinine clearance more or equal to 30 mL/min * Patient informed and consent signature obtained Exclusion Criteria: * Invasive hepatocellular carcinoma without any isolated tumor * Disease needing 2 injections of Therasphere * Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis * Previous treatment by chemoembolization, radiofrequency less than 3 months before radioembolization * No antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including Sorafenib * Associated disease which could prevent patient from receiving treatment * RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or contrast product contre-indication (allergy) * Patient already participating in an other therapeutic trial with an experimental drug * Pregnant or childbearing potential women or breastfeeding women * minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) Unable to comply with trial medical follow-up for geographical, social or psychological reasons * Unable to sign an informed consent